Optimizing oral absorption of peptides using prodrug strategies

Journal of Controlled Release

Volumn 62, Issue 1-2, 1999, Pages 231-238

  Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Caco 2 cells; Cyclic peptide drugs; Membrane permeability; Opioid peptide; Peptide delivery

Indexed keywords

COUMARIN DERIVATIVE; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; LEUCINE ENKEPHALIN DERIVATIVE; OPIATE DERIVATIVE; PHENYLPROPIONIC ACID DERIVATIVE; PRODRUG;

ARTICLE; CHEMICAL REACTION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG METABOLISM; HUMAN; HUMAN CELL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; CACO-2 CELLS; ENDORPHINS; ENKEPHALIN, LEUCINE; ENKEPHALIN, LEUCINE-2-ALANINE; HUMANS; INTESTINAL ABSORPTION; PEPTIDES; PEPTIDES, CYCLIC; PRODRUGS;

EID: 0032827971     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00042-5     Document Type: Article

References (36)

1. Hruby V.J., Gehrig C.C. Recent development in the design of receptor specific opioid-peptides. Med. Res. Rev. 9:1989;343-401.
2. Schiller P.W. Development of receptor-selective opioid peptide analogs as pharmacological tools and as potential drugs. Handbook Exp. Pharmacol. 104:1993;681-710.
3. Abbruscato T.J., Williams S.A., Hruby V.J., Davis T.P. Blood-to-CNS entry and stability of Biphalin, a unique double-enkephalin analogue and its halogenated derivatives. J. Pharmacol. Exp. Ther. 276:1996;1049-1057.
4. Thomas S.A., Abbruscato T.J., Hau V.S., Gillespie T.J., Zsigo J., Hruby V.J., Davis T.P. Structure-activity relationship of a series of [D-Ala2]deltorphin I and II analogues; in vitro blood-brain barrier permeability and stability. J. Pharmacol. Exp. Ther. 281:1997;817-825.
5. Thomas S.A., Abbruscato T.J., Hruby V.J., Davis T.P. The entry of [D-penicillamine-2,5] enkephalin into the central nervous system: saturation kinetics and specificity. J. Pharmacol. Exp. Ther. 280:1997;1235-1240.
6. Bodor N., Prokai L. Molecular packaging: peptide delivery to the central nervous system by sequential metabolism. Taylor M.D., Amidon G.L. Peptide Based Drug Design: Controlling Transport and Metabolism. 1995;317-340 American Chemical Society, Washington DC.
7. Greene D.L., Hau V.S., Abbruscato T.J., Bartosz H., Misicka A., Lipkowski A.W., Hom S., Gillespie T.J., Hruby V.J., Davis T.P. Enkephalin analog prodrugs: assessment of in vitro conversion, enzyme cleavage characterization and blood-brain barrier permeability. J. Pharmacol. Exp. Ther. 277:1996;1366-1375.
8. Misicka A.M., Lipkowski A.W., Stropova D., Yamamura H.I., Hruby V.J. Syntheses and biological properties of gamma-glutamyl-dermorphin, a prodrug. Life Sci. 58:1996;905-911.
9. Patel D., McKinley B.D., Davis T.P., Porreca F., Yamamura H.I., Hruby V.J. Peptide targeting and delivery across blood-brain barrier utilizing triglyceride esters: design, syntheses, and bioactivity. Bioconjug. Chem. 8:1997;434-441.
10. Pardridge W.M. Vector mediated peptide drug delivery to the brain. Adv. Drug. Deliv. Rev. 15:1995;109-146.
11. Pauletti G.M., Gangwar S., Siahaan T.J., Aubé J., Borchardt R.T. Improvement of oral bioavailability: peptidomimetics and prodrug strategies. Adv. Drug Deliv. Rev. 27:1997;235-256.
12. Pauletti G.M., Okumu F.W., Borchardt R.T. Effect of size and charge on the passive diffusion of peptides across Caco-2 cell monolayers via the paracellular pathway. Pharm. Res. 14:1997;164-168.
13. Ramaswami V., Haaseth R.C., Matsunaga T.O., Hruby V.J., O'Brien D.F. Opioid peptide interactions with lipid bilayer membrane. Biochim. Biophys. Acta. 1109:1992;195-202.
14. Conradi R.A., Burton P.S., Borchardt R.T. Physicochemical and biochemical factors that influence a drug's cellular permeability by passive diffusion. Pliska V., Testa B., Waterbeend H.V. Lipophilicity in Drug Action and Toxicity. 1996;233-252 VCH, Weinheim.
15. Burton P.S., Conradi R.A., Ho N.F.H., Hilgers A.R., Borchardt R.T. How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 85:1996;1336-1340.
16. Abbruscato T.J., Thomas S.A., Hruby V.J., Davis T.P. Blood-brain barrier permeability and bioavailability of a highly potent mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J. Pharmacol. Exp. Ther. 280:1997;402-409.
17. Gangwar S., Pauletti G.M., Wang B., Siahaan T.J., Stella V.J., Borchardt R.T. Prodrug strategies to enhance the intestinal absorption of peptides. Drug Discovery Today. 2:1997;148-155.
18. Oliyai R. Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv. Drug Delivery. Rev. 19:1996;275-286.
19. Gangwar S., Jois S.D.S., Siahaan T.J., Vander Velde D.G., Stella V.J., Borchardt R.T. The effect of conformation on membrane permeability of an acyloxyalkoxy-linked cyclic prodrug of a model hexapeptide. Pharm. Res. 13:1996;1657-1662.
20. Gangwar S., Pauletti G.M., Siahaan T.J., Stella V.J., Borchardt R.T. Synthesis of a novel esterase-sensitive cyclic prodrug of a model hexapeptide using an acyloxyalkoxy pro-moiety. J. Org. Chem. 62:1997;1356-1362.
21. Pauletti G.M., Gangwar S., Okumu F.W., Siahaan T.J., Stella V.J., Borchardt R.T. Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide. Pharm. Res. 13:1996;1615-1623.
22. Pauletti G.M., Gangwar S., Wang B., Borchardt R.T. Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropionic acid promoiety in a model hexapeptide. Pharm. Res. 14:1997;11-17.
23. Wang B., Gangwar S., Pauletti G.M., Siahaan T.J., Borchardt R.T. Synthesis of a unique esterase-sensitive cyclic prodrug system for peptides that utilize a trimethyl-lock-facilitated lactonization reaction. J. Org. Chem. 62:1997;1363-1367.
24. A. Bak, T.J. Siahaan, O.S. Gudmundsson, S. Gangwar, G.J. Friis, R.T. Borchardt, Synthesis and evaluation of the physicochemical properties of esterase-sensitive prodrugs of opioid peptides using an (acyloxy)alkoxy linker, J. Peptide Res., in press.
25. B. Wang, K. Nimkar, W. Wang, H. Zhang, D. Shan, O.S. Gudmundsson, S. Gangwar, T.J. Siahaan, R.T. Borchardt, Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using phenylpropionic acid and coumarinic acid linkers, J. Peptide Res., in press.
26. Wang B., Wang W., Zhang H., Shan D., Smith T.D. Coumarin-based prodrugs 2. Synthesis and bioreversibility studies of an esterase-sensitive cyclic prodrugs of DADLE, an opioid peptide. Bioorg. Med. Chem. Lett. 6:1996;2823-2826.
27. Gudmundsson O.S., Pauletti G.M., Wang W., Shen D., Zhang H., Wang B., Borchardt R.T. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability. Pharm. Res. 16:1999;7-15.
28. Hidalgo I.J., Raub T.J., Borchardt R.T. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal permeability. Gastroenterology. 96:1989;736-749.
29. Bailey C.A., Bryla P., Malick A.W. The use of the intestinal epithelial cell model, Caco-2, in pharmaceutical development. Adv. Drug Deliv. Rev. 22:1996;85-103.
30. O.S. Gudmundsson, S.D.S. Jois, D.G. Vander Velde, T.J. Siahaan, B. Wang, R.T. Borchardt, The effect of conformation on the membrane permeability of coumarinic acid- and phenylpropionic acid-base cyclic prodrugs of opioid peptides, J. Peptide Res., in press.
31. Watkins P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug. Deliv. Rev. 27:1997;161-170.
32. Hunter J., Hirst B.H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting drug absorption. Adv. Drug. Deliv. Rev. 25:1997;129-157.
33. Gudmundsson O.S., Nimkar K., Gangwar S., Borchardt R.T. Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability. Pharm. Res. 16:1999;16-23.
34. Bak A., Gudmundsson O.S., Friis G.J., Siahaan T.J., Borchardt R.T. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of their chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers. Pharm. Res. 16:1999;24-29.
35. O.S. Gudmundsson, D.G. Vander Velde, S.D. Jois, A. Bak, T.J. Siahaan, R.T. Borchardt. The effect of conformation on the membrane permeability of acyloxyalkoxy-based cyclic prodrugs of opioid peptides, J. Peptide Res., in press.
36. Camenisch G.P., Wang W., Wang B., Borchardt R.T. A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics. Pharm. Res. 15:1999;1174-1181.